Stock listing

NASDAQ:NGNE Neurogene Inc. Stock

Home listing (NASDAQ) of Neurogene Inc.

Follow Neurogene Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NGNE

$22.15 USD -0.99 (-4.3%)

Close on Nov 20, 2026

Past year +8.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$22.03 – $22.90 USDNov 20, 2026
Volume
178,264 sharesNov 20, 2026
Market cap
$458.5M USDAt the close on Nov 20, 2026 · price × 20.70M shares outstanding
52-week range
$15.93 – $43.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9.05M USDMedian day 232,132 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Neurogene Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NGNE · Home$22.15 USD-0.99 (-4.3%)178,264$22.27$22.90$22.03$23.14Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NGNE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$22.15-0.99-4.3%$22.27$22.90$22.03178,264
$23.14+0.04+0.2%$22.97$23.74$22.28248,968
$23.10-0.20-0.9%$23.38$23.38$22.21278,142
$23.30-0.63-2.6%$23.95$24.65$23.18244,301
$23.93+0.03+0.1%$23.96$24.50$23.29193,616
$23.90-1.20-4.8%$24.77$24.99$22.70237,849
$25.10-0.18-0.7%$25.53$26.94$24.83199,762
$25.28-0.72-2.8%$25.22$26.35$24.22344,519
$26.00+0.69+2.7%$26.26$26.75$24.45442,080
$25.31-0.34-1.3%$26.33$27.26$24.68324,879
$25.65-1.93-7.0%$27.61$28.50$25.57380,728
$27.58+0.91+3.4%$27.79$28.10$26.15208,910
$26.67+0.06+0.2%$27.11$28.59$26.43186,619
$26.61-0.94-3.4%$27.85$29.23$26.47173,618
$27.55-1.27-4.4%$28.53$29.38$26.77249,044
$28.82-1.60-5.3%$30.50$32.09$28.50309,992
$30.42+3.43+12.7%$26.99$31.14$25.81646,309
$26.99+3.45+14.7%$23.71$27.23$23.26484,939
$23.54-0.010.0%$23.75$24.43$23.32123,200
$23.55-0.73-3.0%$24.11$24.11$23.08124,512
$24.28-1.80-6.9%$25.74$26.38$24.09212,380
$26.08+0.68+2.7%$25.52$26.94$25.11588,807
$25.40+1.23+5.1%$24.20$25.84$23.80205,897
$24.17+0.92+4.0%$23.26$24.39$22.78240,177
$23.25-0.70-2.9%$24.00$24.27$23.00571,531
$23.95+1.77+8.0%$22.35$24.41$22.35587,986
$22.18+0.62+2.9%$21.05$22.50$21.05522,546
$21.56-2.88-11.8%$24.32$25.17$21.40442,253
$24.44-1.96-7.4%$26.13$27.15$24.19388,006
$26.40-0.10-0.4%$28.90$29.63$26.01465,903
$26.50+0.63+2.4%$28.00$28.97$26.24509,475
$25.87+0.42+1.7%$25.14$26.01$25.01114,069
$25.45-1.02-3.9%$26.63$26.74$25.04121,651
$26.47+0.82+3.2%$25.71$26.76$24.87211,773
$25.65-0.90-3.4%$26.95$26.95$24.86401,641
$26.55-1.27-4.6%$27.68$28.54$26.44182,600
$27.82-0.57-2.0%$28.52$28.62$27.40160,126
$28.39-0.09-0.3%$28.50$29.16$28.05176,742
$28.48+0.17+0.6%$28.20$28.82$27.64176,387
$28.31-2.94-9.4%$31.31$31.31$28.23200,108
$31.25+0.32+1.0%$30.85$31.78$30.43374,883
$30.93-2.67-7.9%$33.49$33.53$30.09276,187
$33.60+1.03+3.2%$32.94$34.45$32.791,223,247
$32.57+0.48+1.5%$32.09$32.84$31.21325,534
$32.09-0.32-1.0%$32.49$33.15$31.861,388,879
$32.41-2.26-6.5%$35.36$35.64$32.04171,608
$34.67+0.98+2.9%$34.04$34.86$33.53232,132
$33.69-1.52-4.3%$35.04$35.04$33.46147,611
$35.21-0.27-0.8%$35.92$36.28$34.70194,666
$35.48-0.64-1.8%$36.50$37.64$35.38181,388
$36.12-1.76-4.6%$37.51$38.25$36.07177,111
$37.88-0.25-0.7%$38.04$40.42$37.86193,179
$38.13-0.47-1.2%$37.79$38.75$36.68228,474
$38.60+0.99+2.6%$37.25$39.38$36.56205,633
$37.61-0.75-2.0%$38.74$39.19$36.65255,221
$38.36+0.49+1.3%$37.97$39.78$36.86252,961
$37.87+1.63+4.5%$35.80$38.21$35.31134,478
$36.24-0.34-0.9%$36.13$36.64$35.26120,388
$36.58-1.28-3.4%$37.68$38.56$36.32132,795
$37.86-0.55-1.4%$38.50$39.81$37.39149,922
$38.41-2.43-6.0%$40.74$41.77$38.27180,171
$40.84+1.20+3.0%$40.09$42.01$39.13504,339
$39.64+1.01+2.6%$38.64$40.82$37.50439,100
$38.63+0.64+1.7%$38.41$39.44$37.54346,580
$37.99-1.44-3.7%$38.55$38.60$36.78124,693

Splits

2 splits since 2023 · NASDAQ:NGNE · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
1-for-5Consolidation
Ticker
NASDAQ:NGNE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Neurogene Inc. news

Neurogene Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 104 in all · newest Nov 9, 2026 · oldest 2020
Calls
2 calls with a replay · 2 with a transcript · latest Aug 9, 2022
Decks
26 decks · latest Nov 9, 2026

Where Neurogene Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NGNE · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3EX79LS ExchangeGermanyEUR
Lang & Schwarz:A3EX79Lang & SchwarzGermanyEUR
BOATS:NGNEBOATSUnited StatesUSD
Frankfurt:UU8FrankfurtGermanyEUR
Dusseldorf:UU8DusseldorfGermanyEUR
Tradegate:UU8TradegateGermanyEUR
Stuttgart:UU8StuttgartGermanyEUR

Valuation

Price/book 1.3× against a median of 2.6×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$106.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
G2GBIO, Inc. · KRX:456160US$449.2MUS$289.1Mn/a176×n/a4.3×−793.7%0.0×n/a
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Hansa Biopharma AB · OMXSTO:HNSAUS$441.5MUS$488.7Mn/a26.3×n/an/a−406.5%n/an/a
Median of the othersUS$454.3MUS$289.0M7.0×2.6×−406.5%0.0×1.21

Forecasts

9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
77.25 USD · Analysts' mean
EPS, year to Dec 2026
-4.98 · 2 analysts

Team and board

Officers

OfficerRole
Rachel McMinnFounder and Chief Executive Officer
Christine MikailPresident and Chief Financial Officer
Keith WoodsChief Operating Officer
Donna M. CochenerSenior Vice President and General Counsel
Lina LiExecutive Director, Investor Relations
Mike DevineExecutive Director, Corporate Communications
Andrew MulbergSenior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control
Arvind SreedharanSenior Vice President, Business Operations
Ricardo JimenezSenior Vice President, Technical Operations
Christy ShaferChief Commercial Officer
Julie JordanChief Medical Officer
Sarah B. NoonbergChief Medical Officer
Stuart CobbChief Scientific Officer

Board

DirectorRole
Lina LiExecutive Director, Investor Relations
Mike DevineExecutive Director, Corporate Communications

Events

Calls

CallWhenStatus
Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings CallTue, Aug 09, 2022 · 4:30 PM ETReplay
Neoleukin Therapeutics, Inc. (NLTX) Q4 2021 Earnings CallTue, Mar 01, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−2.8%
Q2 2026Aug 11, 2026 · After close+3.3%
Q1 2026May 13, 2026−0.9%
Q4 2025Mar 24, 2026 · After close+5.4%
Q3 2025Nov 13, 2025 · After close−14.0%
Q2 2025Aug 11, 2025 · After close−5.5%
Q1 2025May 8, 2025 · Before open+8.2%
Q4 2024Mar 24, 2025 · After close+1.7%
Q3 2024Nov 18, 2024 · After close−13.1%
Q2 2024Aug 9, 2024 · Before open−2.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · After close−5.7%
Q4 2023Mar 18, 2024 · After close+20.0%
Q3 2023Nov 14, 2023+2.7%
Q2 2023Aug 16, 2023+8.1%
Q1 2023May 10, 2023−0.9%
Q4 2022Mar 16, 2023+4.6%
Q3 2022Nov 14, 2022−21.4%
Q2 2022Aug 9, 2022−7.2%
Q1 2022May 9, 2022−6.5%
Q4 2021Mar 1, 2022+5.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck38 slidesNov 9, 2026
Investor Presentation (August 2026)Investor deck37 slidesAugust 2026
Technical Presentation (June 2026)Technical38 slidesJun 29, 2026
Investor Presentation (June 2026)Investor deck33 slidesJun 8, 2026
Investor Presentation (May 2026)Investor deck33 slidesMay 12, 2026
Investor Presentation (March 2026)Investor deck33 slidesMar 24, 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck35 slidesNov 13, 2025
Corporate Update (November 2025)Corporate update22 slidesNov 12, 2025
Investor Presentation (November 2025)Investor deck36 slidesNov 6, 2025
All 26 decks
DeckKindSlidesDate
Investor Presentation (October 2025)Investor deck35 slidesOct 9, 2025
Investor Presentation (August 2025)Investor deck35 slidesAug 11, 2025
Investor Presentation (June 2025)Investor deck35 slidesJun 30, 2025
Investor Presentation (June 2025)Investor deck43 slidesJun 9, 2025
2025 IRSF Rett Syndrome Scientific MeetingConference16 slidesJune 2025
2025 ASGCT MeetingConference10 slidesMay 16, 2025
Investor Presentation (March 2025)Investor deck49 slidesMar 24, 2025
Investor Presentation (January 2025)Investor deck50 slidesJan 13, 2025
Technical Presentation (November 2024)Technical46 slidesNov 12, 2024
Investor Presentation (August 2024)Investor deck37 slidesAug 9, 2024
Investor Presentation (June 2024)Investor deck37 slidesJun 21, 2024
Investor Presentation (May 2024)Investor deck36 slidesMay 10, 2024
Investor Presentation (March 2024)Investor deck36 slidesMar 4, 2024
Investor Presentation (January 2024)Investor deck35 slidesJan 5, 2024
Neoleukin Therapeutics — Merger or Acquisition (July 2023)Merger or acquisition34 slidesJul 18, 2023
ASGCT 2023Conference15 slides2023

Open Decks

Financings

RaiseDate
Public offering of shares
Closed: US$144M raised
Aug 11, 2026
Public offering of shares of common stock and pre-funded warrants
Update: about US$125M · US$30 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), William Blair (co-lead)
Use of proceeds: Fund clinical development and pre-commercial activities for NGN-401, working capital and general corporate purposes
Jul 1, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as AQUINOX PHARMACEUTICALS, INC. Priced at US$11.00 a share on Mar 6, 2014.

Price
US$11.00 a share
Shares offered
4,200,000 shares of common stock
Offering size
US$46.2 million
Underwriters' option
Up to 630,000 more shares
Underwriters
Jefferies, Cowen and Company, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Mar 12, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceNov 18, 2013
Filed publiclyJan 28, 2014
Amended onceFeb 28, 2014
Shares registered with an exchangeMar 3, 2014
Declared effective by the SECMar 6, 2014
Final prospectus, with the priceMar 7, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Mar 7, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0925.0K00025.0M
Cost of revenue3.19M3.25M3.26M3.20M42.3M1.82M340.0K
Gross profit-3.19M-2.32M-3.26M-3.20M-42.3M-1.82M-340.0K25.0M
Research and development75.0M60.9M44.4M47.5M39.2M24.3M4.42M41.8M36.3M28.4M
Selling, general and administrative28.3M22.6M11.2M9.01M8.27M
Operating income-103.3M-82.6M-55.6M-56.5M-60.7M-33.7M-71.0M-32.6M-51.1M-37.6M
Depreciation and amortization3.04M3.19M3.26M3.20M1.31M785.0K340.0K289.0K360.0K1
EBITDA-100.3M-79.4M-52.3M-53.3M-59.4M-32.9M-70.6M-32.3M-50.8M-37.6M
Interest expense5.00K12.0K12.0K2.00K01.00K4.00K4.00K1.00K
Income before tax-90.4M-75.1M-36.3M-55.2M-60.7M-33.3M-69.4M-31.6M-50.2M-37.0M
Income tax00-16.0K-5.00K17.0K-1168.1K-10
Net income-90.4M-75.1M-36.3M-55.2M-60.7M-33.3M-69.4M-31.6M-50.2M-37.0M
Earnings per share, basic-4.24-4.28-2.83-1.04-1.10-0.64-2.57-1.34-2.14-1.96
Earnings per share, diluted-4.24-4.28-1.04-1.10-0.64-2.57-1.34-2.14-1.96

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents103.8M136.6M148.2M82.0M142.5M192.6M143.1M76.9M52.0M32.3M
Short-term investments165.2M175.8M48.9M0056.1M70.8M
Receivables648.0K600.0K990.0K790.0K
Inventory1.50M1.08M1.91M
Current assets271.8M315.9M200.3M84.7M144.0M194.5M143.6M77.2M108.8M103.5M
Property, plant and equipment12.8M15.4M17.2M20.1M6.45M3.57M2.06M400.0K905.0K849.0K
Total assets288.6M335.7M222.6M109.3M163.3M210.5M147.0M77.6M110.3M154.4M
Accounts payable1.95M1.34M2.60M625.0K5.63M1.32M1.60M702.0K
Current liabilities16.4M15.2M23.0M6.65M8.64M7.89M4.74M4.63M11.0M9.52M
Total debt9.89M12.4M16.3M4.69M6.43M12.1M1.21M6.00K33.0K47.0K
Total liabilities23.7M25.4M36.5M10.6M20.4M19.3M5.34M4.95M11.4M9.72M
Shareholders' equity264.9M310.4M186.0M-145.7M-91.9M191.2M141.7M72.7M98.9M144.7M
Shares outstanding15.5M14.9M12.8M042.5M42.2M38.0M23.5M23.5M23.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-77.2M-70.6M-51.4M-52.8M-47.6M-24.6M-15.4M-31.6M-44.7M-30.2M
Capital spending-1.18M-808.0K-321.0K-2.23M-3.26M-2.22M-879.0K-49.0K-494.0K-713.0K
Free cash flow-78.4M-71.4M-51.7M-55.1M-50.8M-26.8M-16.3M-31.6M-45.2M-30.9M
Cash from investing14.0M-125.3M25.6M-2.23M-3.26M-2.22M-688.0K56.0M64.0M-48.1M
Cash from financing30.4M184.1M92.5M66.5M732.0K77.1M82.2M570.0K423.0K71.1M
Change in cash-32.7M-11.8M66.7M11.5M-50.1M50.3M66.2M24.9M19.7M-7.22M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 6, 2026Big-stake noticeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
8-K · Current reportJul 1, 2026Material contractSEC
424B5 · ProspectusJul 1, 2026Offer documentSEC
424B5 · ProspectusJun 30, 2026Offer documentSEC
8-K · Current reportJun 29, 2026Current reportSEC
4/A · Change in ownership, amendedJun 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 16, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedJun 16, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Current reportSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
8-K · Current reportMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
3 · Initial statement of ownershipApr 20, 2026Insider tradeSEC
8-K · Current reportApr 20, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 24, 2026Offer documentSEC
10-K · Annual reportMar 24, 2026Annual reportSEC
8-K · Current reportMar 24, 2026ResultsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
144 · Notice of proposed saleMar 13, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
8-K · Current reportFeb 26, 2026Current reportSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025Current reportSEC
8-K · Current reportNov 6, 2025Current reportSEC
8-K · Current reportOct 9, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
424B5 · ProspectusAug 11, 2025Offer documentSEC
8-K · Current reportAug 11, 2025ResultsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportJun 30, 2025Current reportSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Management or board changeSEC
8-K · Current reportJun 9, 2025Current reportSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
144 · Notice of proposed saleMay 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
8-K · Current reportMay 9, 2025ResultsSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
8-K · Current reportApr 14, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 7, 2025Other filingsSEC
CORRESP · Letter to the SECApr 2, 2025Other filingsSEC
424B3 · ProspectusApr 1, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 31, 2025Other filingsSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
S-3 · Registration statementMar 24, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 24, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 24, 2025Offer documentSEC
8-K · Current reportMar 24, 2025ResultsSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
424B3 · ProspectusDec 18, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 17, 2024Other filingsSEC
CORRESP · Letter to the SECDec 12, 2024Other filingsSEC
SC 13G · Big-stake noticeDec 11, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECDec 9, 2024Other filingsSEC
S-1 · Registration statementDec 2, 2024Offer documentSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 27, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 27, 2024Big-stake noticeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
8-K · Current reportNov 21, 2024Current reportSEC
10-Q · Quarterly reportNov 18, 2024Quarterly reportSEC
8-K · Current reportNov 18, 2024ResultsSEC
8-K · Current reportNov 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
NT 10-Q · Late filing noticeNov 14, 2024Explanation requestSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024Current reportSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 4, 2024Material contractSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
8-K · Current reportAug 7, 2024Current reportSEC
SC 13G · Big-stake noticeJul 8, 2024Big-stake noticeSEC
8-K · Current reportJun 21, 2024Current reportSEC
8-K · Current reportJun 18, 2024Current reportSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
8-K · Current reportJun 3, 2024Current reportSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
8-K · Current reportMay 10, 2024ResultsSEC
8-K · Current reportMay 7, 2024Current reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 24, 2024Management or board changeSEC
8-K · Current reportApr 22, 2024Current reportSEC
8-K · Current reportApr 2, 2024Management or board changeSEC
8-K · Current reportMar 18, 2024ResultsSEC
10-K · Annual reportMar 18, 2024Annual reportSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
144 · Notice of proposed saleMar 7, 2024Other filingsSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
8-K · Current reportMar 4, 2024Current reportSEC
8-K · Current reportFeb 21, 2024Management or board changeSEC
S-8 · Registration statement for employee plansFeb 20, 2024Offer documentSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 9, 2024Other filingsSEC
144 · Notice of proposed saleFeb 6, 2024Other filingsSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 18, 2024Insider tradeSEC
8-K · Current reportJan 5, 2024Current reportSEC
SC 13G · Big-stake noticeDec 27, 2023Big-stake noticeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedDec 22, 2023Big-stake noticeSEC
SC 13D · Big-stake noticeDec 21, 2023Big-stake noticeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 20, 2023Big-stake noticeSEC
8-K · Current reportDec 19, 2023Acquisition or disposalSEC
425Dec 6, 2023Other filingsSEC
8-K · Current reportDec 6, 2023Current reportSEC
425Dec 4, 2023Other filingsSEC
8-K · Current reportDec 4, 2023Current reportSEC

This page holds 200 of 756 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Neurogene Inc.’s releases · as of Nov 5, 2026

Common shares
20,700,905
Fully diluted
20,700,905

Fully diluted

LineSharesAs of
Common shares20,700,905Nov 5, 2026

Share count over time

CountShares
Nov 5, 202620,700,905

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Jennison Associates LLC2.23MUS$62M+1.71MNov 13, 2026
Samsara Biocapital, LLC1.87MUS$51.9M+150KNov 16, 2026
Casdin Capital, LLC1.59MUS$44.1M+40,000Nov 16, 2026
Redmile Group, LLC1.56MUS$43.5M+150KNov 16, 2026
Rtw Investments, LP1.51MUS$42.1M+150KNov 16, 2026
BlackRock1.47MUS$40.9M+414KNov 13, 2026
EcoR1 Capital, LLC1.27MUS$35.4MNo changeNov 16, 2026
Vanguard1000KUS$27.8M+289KNov 13, 2026
Baker Bros. Advisors LP992KUS$27.6MNo changeNov 16, 2026
Trails Edge Capital Partners, LP965KUS$26.8M+250KNov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
T. Rowe Price863KUS$24M+854KNov 16, 2026
Mpm Bioimpact LLC772KUS$21.5MNewNov 16, 2026
TD701KUS$19.5M+20,028Nov 16, 2026
Franklin Templeton631KUS$17.4M+427KNov 12, 2026
State Street549KUS$15.3M+325KNov 12, 2026
UBS421KUS$11.7M+249KNov 16, 2026
Geode Capital413KUS$11.5M+120KNov 6, 2026
Fidelity383KUS$10.7M+87,688Nov 10, 2026
ArrowMark Colorado Holdings LLC379KUS$10.5M+36,376Nov 16, 2026
Tyro Capital Management LLC304KUS$8.47MNewNov 12, 2026
Balyasny Asset Management L.P.304KUS$8.46M−515KNov 16, 2026
Great Point Partners LLC300KUS$8.35M−52,180Nov 16, 2026
Point72 Asset Management, L.P.239KUS$6.65M+97,047Nov 16, 2026
Morgan Stanley221KUS$6.15M+29,366Nov 13, 2026
Driehaus Capital Management LLC219KUS$6.08M+75,000Nov 16, 2026
Jones Hill Capital LP218KUS$6.06MNewNov 13, 2026
Integral Health Asset Management, LLC200KUS$5.56MNewNov 16, 2026
Moore Capital Management, LP181KUS$5.05M+39,843Nov 16, 2026
Marshall Wace, LLP169KUS$4.69MNewNov 13, 2026
Rock Springs Capital Management LP154KUS$4.3M+47,651Nov 16, 2026
DAFNA Capital Management LLC151KUS$4.19M+61,500Nov 16, 2026
Northern Trust133KUS$3.7M+29,393Nov 16, 2026
Goldman Sachs121KUS$3.37M+19,917Nov 16, 2026
Vestal Point Capital, LP115KUS$3.2MNewNov 16, 2026
DWS108KUS$3M+1,289Nov 6, 2026
Citadel92,858US$2.58M−316KNov 16, 2026
Dimensional87,700US$2.44M+55,072Nov 4, 2026
Woodline Partners LP83,835US$2.33MNo changeNov 16, 2026
Blair William & Co79,081US$2.2M−67,824Nov 10, 2026
JPMorgan61,953US$1.76M+71Nov 12, 2026
Burkehill Global Management, LP60,000US$1.67MNewNov 16, 2026
Bank of America51,171US$1.42M+40,047Nov 16, 2026
Schwab49,589US$1.38M+16,847Nov 16, 2026
ADAR1 Capital Management, LLC43,800US$1.22M+36,000Nov 16, 2026
Trexquant Investment LP43,503US$1.21M−30,259Nov 16, 2026
Wellington40,732US$1.13M+9,339Nov 16, 2026
BNY38,710US$1.08M+9,969Nov 5, 2026
Nuveen35,994US$1M+8,170Nov 10, 2026
Raiffeisen Bank International AG34,000US$965KNo changeOct 28, 2026
American Century30,063US$836K+6,733Nov 20, 2026

This page holds 50 of 125 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Vanguard Total Stock Market Index Fund398KUS$12.5M+15,600Jun 30, 2026
iShares Russell 2000 ETF296KUS$9.32M+25,861Jun 30, 2026
Franklin Biotechnology Discovery Fund219KUS$7.2MNewJul 31, 2026
Fidelity Advisor Biotechnology Fund177KUS$5.83M−66,500Jul 31, 2026
Vanguard Extended Market Index Fund127KUS$3.99M+6,196Jun 30, 2026
Fidelity Small Cap Index Fund124KUS$4.08M+12,146Jul 31, 2026
iShares Russell 2000 Value ETF105KUS$3.31M+8,729Jun 30, 2026
Fidelity Enhanced Small Cap Core ETF90,867US$2.86M+13,018Jun 30, 2026
iShares Biotechnology ETF88,398US$2.78M−6,296Jun 30, 2026
Meridian Small Cap Growth Fund75,859US$2.39MNo changeJun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Vanguard Russell 2000 Index Fund57,993US$1.64M+9,489May 31, 2026
Fidelity Extended Market Index Fund55,794US$1.58M−1,061May 31, 2026
Select Biotechnology Portfolio51,100US$1.45MNo changeMay 31, 2026
iShares Micro-Cap ETF37,552US$1.18M+9,127Jun 30, 2026
Schwab Small-Cap Index Fund27,503US$905K+2,684Jul 31, 2026
Master Small Cap Index Series20,627US$649K+3,799Jun 30, 2026
Avantis U.S. Small Cap Equity ETF20,446US$579K+3,895May 31, 2026
Ultra-Small Company Market Fund18,781US$591KNo changeJun 30, 2026
Fidelity Total Market Index Fund18,774US$532KNo changeMay 31, 2026
Fidelity Series Total Market Index Fund16,206US$459K+879May 31, 2026
ALPS Medical Breakthroughs ETF15,968US$453K+2,162May 31, 2026
Fidelity Small Cap Value Index Fund15,827US$498K+1,855Jun 30, 2026
JPMorgan U.S. Small Company Fund15,498US$487K−1,119Jun 30, 2026
Nuveen Small Cap Blend Index Fund15,005US$494K+2,614Jul 31, 2026
Dimensional U.S. Small Cap ETF12,679US$417K+4,266Jul 31, 2026
U.S. Micro Cap Portfolio12,271US$404K+11,550Jul 31, 2026
EQ/2000 Managed Volatility Portfolio11,896US$374KNo changeJun 30, 2026
Virtus Biotech Clinical Trials Etf10,681US$351K−2,512Jul 31, 2026
Fidelity Nasdaq Composite Index Fund10,287US$292K+2,446May 31, 2026
JPMorgan Small Cap Value Fund9,770US$307K−597Jun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund9,344US$307KNewJul 31, 2026
Nuveen Equity Index Fund8,852US$291KNo changeJul 31, 2026
Vanguard Russell 2000 Value Index Fund8,684US$246K+1,524May 31, 2026
EQ/Small Company Index Portfolio8,240US$259K+1,600Jun 30, 2026
LVIP State Street Small-Cap Index Fund7,100US$223KNo changeJun 30, 2026
Vanguard Balanced Index Fund6,409US$202K−859Jun 30, 2026
Fidelity ZERO Total Market Index Fund5,853US$193K+258Jul 31, 2026
Small Cap Index Fund5,675US$178K−182Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund5,645US$178K+909Jun 30, 2026
Global X Russell 2000 ETF5,395US$177K+520Jul 31, 2026
Schwab Total Stock Market Index Fund5,239US$172KNo changeJul 31, 2026
Bridge Builder Small/Mid Cap Value Fund4,657US$146KNo changeJun 30, 2026
EQ/AB Small Cap Growth Portfolio4,530US$142K+1,600Jun 30, 2026
iShares Russell 3000 ETF4,401US$138K−35Jun 30, 2026
U.S. Vector Equity Portfolio4,300US$141KNewJul 31, 2026
Small Cap Index Fund4,187US$119K+215May 31, 2026
Fidelity ZERO Extended Market Index Fund4,065US$134K+159Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF3,984US$131K+1,918Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio3,800US$120KNo changeJun 30, 2026
Nationwide Bailard Small Cap Value Fund3,625US$119KNo changeJul 31, 2026

This page holds 50 of 124 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale4,200USD 36.13US$152KJul 7, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale600USD 36.02US$21,612Jul 6, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale2,531USD 34.58US$87,522Jul 2, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale1,530USD 35.23US$53,902Jul 2, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale739USD 34.06US$25,170Jul 1, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale4,800USD 30.07US$144KMay 6, 2026
Cvijic Christine Mikail
Director, Officer: President and CFO
Sale4,800USD 32.44US$156KMay 6, 2026

Big stakes

HolderStakeSharesDate
PRUDENTIAL FINANCIAL INC11.20%2.23MSep 30, 2026
Jennison Associates LLC11.10%2.23MSep 30, 2026
Redmile Group, LLC9.90%1.57MJun 30, 2026
EcoR1 Capital, LLC9.90%1.44MSep 30, 2025
Srinivas Akkaraju9.70%1.95MSep 30, 2026
Rtw Investments, LP9.30%1.9MSep 30, 2026
Casdin Capital, LLC8.70%1.3MDec 31, 2024
BlackRock, Inc.6.80%1.01MMar 31, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Felix Baker
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past)
Director · May 8, 2017 – Dec 18, 2023 · Past
Julian Baker
Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past)
Director · May 8, 2017 – Dec 18, 2023 · Past
Martin Babler
Other companies: MapLight Therapeutics, Inc. (Member of the Audit Committee · Since at least Jun 23, 2026); Alumis Inc. (President, Chief Executive Officer and Chairman of the Board · Since at least Jun 27, 2024); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jul 19, 2021); Omega Alpha SPAC (Director · Jan 6, 2021 – Jan 6, 2021 · Past); Principia Biopharma Inc (President, CEO, Director · Sep 13, 2018 – Sep 28, 2020 · Past); ZS Pharma Inc (Director · Mar 19, 2015 – Dec 17, 2015 · Past)
Director · Sep 8, 2020 – Jun 8, 2023 · Past
Kelvin Neu
Other companies: Theravance Biopharma, Inc. (MD, PhD · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Mar 16, 2020); Prelude Therapeutics Incorporated (Director · Sep 24, 2020 – Sep 24, 2020 · Past); IGM Biosciences Inc (Director · Sep 17, 2019 – Sep 17, 2019 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Mar 10, 2014 · Past)
Director · Mar 23, 2017 – Mar 23, 2017 · Past
Sean P. Nolan
Other companies: Taysha Gene Therapies, Inc. (Chief Executive Officer and Board Chairman · Since at least Sep 23, 2020); Ventas, Inc. (Director · Since at least Jul 26, 2019); Social Capital Suvretta Holdings Corp II (Director · Sep 24, 2021 – Sep 24, 2021 · Past); AveXis Inc (President & CEO, Director · Feb 10, 2016 – May 15, 2018 · Past); InterMune Inc (EVP & CBO · Feb 11, 2013 – Sep 29, 2014 · Past)
Director · Feb 16, 2015 – May 5, 2020 · Past
Erin Lavelle
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past)
Director · May 12, 2022 – Jun 8, 2023 · Past
Keith Woods
Other companies: Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past)
Director · Since at least Jun 12, 2025
Lewis T. Rusty Williams
Other companies: Protagonist Therapeutics, Inc. (Director, Co-Founder, Chairman · Since at least Jun 7, 2017); Arcellx Inc (Director · Feb 3, 2022 – Feb 8, 2022 · Past); Five Prime Therapeutics Inc (Director · Sep 17, 2013 – Sep 1, 2019 · Past); Beckman Coulter Inc (Director · Oct 23, 2009 – Jun 30, 2011 · Past)
Director · Aug 8, 2019 – May 11, 2021 · Past
Christine Mikail Cvijic
Other companies: Sio Gene Therapies Inc (Chief Admin Officer and GC · Jun 10, 2015 – Apr 29, 2016 · Past); NPS Pharmaceuticals Inc (SVP, Legal Affairs & GC · Mar 3, 2014 – Feb 21, 2015 · Past); Dendreon Corp (EVP, Corp Dev, Gen Cnsl/Scrtry · Feb 29, 2012 – Feb 10, 2014 · Past)
President and CFO, Director · Since at least Dec 18, 2023
Gary L. Bridger
Other companies: X4 Pharmaceuticals, Inc. (Board Member · Since at least Mar 13, 2019); Xenon Pharmaceuticals Inc. (EVP, Research & Development · Nov 4, 2014 – Nov 21, 2014 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 31, 2015 · Past)
Director · Mar 6, 2014 – May 7, 2018 · Past
All 42 people
PersonSeat
Jonathan G Drachman
Other companies: Harpoon Therapeutics Inc (Director · Feb 7, 2019 – Mar 8, 2024 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Nov 10, 2021 · Past); Seagen Inc (CMO & EVP, R & D · Oct 1, 2013 – Mar 20, 2018 · Past)
President and CEO, Director · Aug 8, 2019 – Aug 2, 2022 · Past
Robert A. Baffi
Other companies: Mosaic ImmunoEngineering Inc (Director · Since at least Jul 15, 2021); Humanigen Inc (Director · Nov 25, 2014 – Jul 10, 2015 · Past); BioMarin Pharmaceutical Inc. (President, Global Mfg/Tech Ops · Apr 10, 2013 – Mar 20, 2020 · Past)
Director · Since at least Dec 18, 2023
Rohan Palekar
Other companies: 89bio Inc (Chief Executive Officer, Director · Since at least Nov 8, 2019); Avanir Pharmaceuticals Inc (SVP & Chief Commercial Officer · Apr 3, 2012 – Nov 28, 2014 · Past); Medivation Inc (Chief Commercial Officer · Jan 14, 2008 – Apr 20, 2011 · Past)
Director · Since at least Mar 2, 2022
Sarah B. Noonberg
Other companies: Metagenomi Therapeutics, Inc. (Chief Medical Officer · Since at least Feb 8, 2024); Marinus Pharmaceuticals Inc (Director · May 16, 2023 – Jun 18, 2024 · Past); Protagonist Therapeutics, Inc. (Director · Dec 12, 2017 – Jan 16, 2023 · Past)
Director · Since at least Aug 8, 2019
Kamran Alam
Other companies: Taysha Gene Therapies, Inc. (Chief Financial Officer · Since at least Sep 23, 2020); Rocket Pharmaceuticals, Inc. (SVP - Finance & PFO · Oct 28, 2019 – Feb 6, 2020 · Past)
CFO, Vice President Finance · Mar 9, 2018 – Aug 7, 2018 · Past
Todd Simpson
Other companies: Xencor, Inc. (Director · Since at least Mar 13, 2025); Seagen Inc (Chief Financial Officer · Jan 31, 2006 – Dec 14, 2023 · Past)
Director · Mar 6, 2014 – Jun 8, 2023 · Past
Christina Shafer
Other companies: Marinus Pharmaceuticals Inc (CHIEF COMMERCIAL OFFICER · Jun 15, 2022 – Feb 7, 2025 · Past)
Chief Commercial Officer · Since at least Apr 20, 2026
Cory S Freedland
Other companies: Jiya Acquisition Corp (Chief Investment Officer, Director · Nov 18, 2020 – Nov 18, 2020 · Past)
Director · Since at least Dec 18, 2023
Daniel J Levitt
Other companies: Sorrento Therapeutics, Inc. (Director · Jan 30, 2014 – Jan 30, 2014 · Past)
Director · Mar 6, 2014 – May 14, 2018 · Past
Julie Jordan
Other companies: Q32 Bio Inc. (Chief Medical Officer · Mar 7, 2023 – Aug 3, 2023 · Past)
Chief Medical Officer · Since at least Jan 16, 2024
Meta Cantey Boyd
Other companies: Kiniksa Pharmaceuticals International, plc (Director · Oct 4, 2024 – Oct 4, 2024 · Past)
Director · Aug 8, 2019 – Aug 8, 2019 · Past
Rachel McMinn
Other companies: Intercept Pharmaceuticals Inc (Chief Strategy Officer · Apr 30, 2014 – Oct 2, 2017 · Past)
Founder and Chief Executive Officer · Since at least Dec 18, 2023
Robert Ho
Other companies: Third Harmonic Bio Inc. (Chief Financial Officer · Sep 14, 2022 – Mar 6, 2023 · Past)
Chief Financial Officer · Mar 16, 2020 – Feb 1, 2022 · Past
Shelley McCloskey
Other companies: Xenon Pharmaceuticals Inc. (Executive Vice President, Human Resources · Since at least Nov 5, 2026)
VP, HR and Administration · Dec 14, 2015 – Aug 7, 2018 · Past
Abigail JenkinsChief Commercial Officer · Jun 6, 2016 – Mar 9, 2018 · Past
Andrew MulbergSenior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control · Since at least Nov 4, 2026
Arvind SreedharanSenior Vice President, Business Operations · Since at least Nov 5, 2026
Carl WalkeySenior Vice President · Jan 30, 2021 – Aug 2, 2022 · Past
Christine MikailPresident and Chief Financial Officer · Since at least Apr 20, 2026
Christy ShaferChief Commercial Officer · Since at least Apr 20, 2026
David Chilton MitchellVP Global Regulatory & Quality · Aug 11, 2015 – Mar 8, 2017 · Past
David MainPresident and CEO, Director · Mar 6, 2014 – Aug 7, 2018 · Past
Donna M. CochenerSenior Vice President and General Counsel · Since at least Mar 14, 2022
Erin M LavelleDirector · Jun 1, 2020 – May 11, 2021 · Past
Holly VanceGeneral Counsel · Oct 19, 2020 – Aug 3, 2021 · Past
Lina LiExecutive Director, Investor Relations · Since at least Sep 8, 2026
Mike DevineExecutive Director, Corporate Communications · Since at least Sep 8, 2026
Priti PatelChief Medical Officer · Apr 30, 2021 – Feb 1, 2023 · Past
Ricardo JimenezSenior Vice President, Technical Operations · Since at least Nov 5, 2026
Robert Keith WoodsDirector · Since at least Dec 18, 2023
Sean Michael SmithInterim CFO, Prin Acct Off · Mar 2, 2022 – Aug 10, 2023 · Past
Stuart CobbChief Scientific Officer · Since at least Dec 18, 2023

Open People

Log in to ask 6ix AI your own questions about Neurogene Inc.